The oncology conversation keeps moving toward smarter combinations. For $SONA, that matters. The bigger opportunity is not just local treatment, it is where THT may fit inside a broader strategy if it continues to show the right signals. That is the question we are building

One of the most important questions in oncology right now: Can local treatment trigger a broader immune response beyond the treated site? The science is pointing toward yes, under the right conditions. That's why TME modulation and combination approaches are attracting so much

In early-stage oncology, three external signals tend to matter most: 1. Peer-reviewed publication — independent review of the science 2. Conference acceptance — the research community's verdict 3. Publications - Tier of journal and number of views and citations These aren't

Most gold nanorod production uses CTAB, a stabilising agent that is cytotoxic and limits use in humans. $SONA GNRs are CTAB-free. Validated by the NCI Nanotechnology Characterization Laboratory. That is not a footnote. It is the reason THT can be used in humans. Journal of Nanobiotechnology

leadership and platform depth mattering again as capital rotates back. Tartaglia, Kalnin, Lievonen all stacked around DPX. April 28 filing is the next catalyst. $BIOV $BVAXF

PESCO abstract accepted at ASCO 2026. one patient in complete response for 3 years. three tumor types with peer-reviewed or conference-accepted data. breast cancer, bladder, now ovarian. the platform keeps passing external checkpoints. $BIOV $BVAXF thenewswire.com/press-releases…

immunotherapy momentum building and DPX just got ASCO 2026 acceptance for PESCO ovarian data. platform driven biotech getting attention and $BIOV has three tumor types with peer reviewed data. the timing lines up. $BIOV $BVAXF

Deadline day for filings. If $BIOV $BVAXF clears the MCTO, that alone resets the setup. Stack that with ASCO abstract momentum from PESCO + earlier MVP-S data, and you’ve got layered catalysts, not just one headline. Quiet build, multiple triggers.

April 28. BioVaxys annual filing deadline. MCTO lifts if filed today. double disclosure package incoming. watching SEDAR. $BIOV $BVAXF

PESCO trial accepted at ASCO 2026. PI from Princess Margaret Cancer Centre. MVP-S plus Keytruda in recurrent ovarian cancer. peer reviewed, presenting Chicago May 29. $BIOV $BVAXF

data plus first revenue equals repricing zone. that is exactly the BIOV setup today. April 28 filing deadline, double disclosure package, SpayVac Q1 revenue anticipated, ASCO 2026 in May. $BIOV $BVAXF

BioVaxys missed April 28. new deadline May 31. auditor delay, not management. no insolvency, shares still trade. melanoma LOI dropped last night. ASCO May 29. $BIOV $BVAXF

MCTO still on but May 31 is the date. filings land, overhang clears. ASCO May 29 with Dr. Oza from Princess Margaret presenting PESCO data to rooms that include AstraZeneca and GSK advisors. pipeline keeps moving. $BIOV $BVAXF

clean update, no new issues. auditor timing, not a red flag. ASCO May 29, filings May 31. $BIOV $BVAXF

delay stings but the update was clean. no new issues. ASCO PESCO data still coming May 29. DPX keeps delivering while admin catches up. $BIOV $BVAXF

BioVaxys submitted LOI to Melanoma Research Foundation. MVP-S combined with targeted hyperthermia in acral melanoma. Dalhousie University and Sona Nanotech involved. bladder, ovarian, breast, now melanoma. four tumor types and counting. $BIOV $BVAXF

Nature/NPJ Imaging published. MRI tracking tumor response with MVP-S plus anti-PD-1 plus cyclophosphamide. same combination as the PESCO trial. tumor volume significantly lowered, immune cells increased. peer reviewed, independently validated. $BIOV $BVAXF

Nature/NPJ Imaging just published peer reviewed DPX science. same combo as PESCO trial. tumor volume down, immune cells up. platform keeps validating while the sector rotates. $BIOV $BVAXF